Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date Creating 3D Organoid Models of Small Cell Lung Cancer Amanda Linkous, Ph.D. Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is clinically more aggressive than non-small cell lung cance... 1 year ago | 39 mins Key Notables on IHC Interpretation of PD-L1 SP263 on FNA samples Dr. Dorothy Hayden, Pathologist, Companion Diagnostic, at Roche Tissue Diagnostics Dr. Dorothy Hayden, Staff Pathologist, Companion Diagnostics with Roche Tissue Diagnostics, will discuss key insights that can be applied to successfu... 3 years ago | 40 mins Cost effectiveness analysis of PD-L1 testing in NSCLC - IVD vs LDT Jason Hurwitz, BA, MA, Phd; Shannon Vaffis, MPH, Phd; Amy Grizzle, BA, Pharm D This webinar will share compelling research that evaluated the cost-effectiveness of PD-L1 testing with an in vitro diagnostic (IVD) compared to a lab... 11 months ago | 45 mins Small Cell Lung Cancer Dr. Erik Thunnissen, FBJM Small Cell Lung Cancer presented by Dr. Erik Thunnissen, FBJM, Department of Pathology, VU University Medical Center Amsterdam, the Netherlands. 4 years ago | 30 mins Lung Cancer Diagnostics: Evolving Practice and Future Directions Professor Keith Kerr Personalized medicine for non-small-cell lung cancer (NSCLC) continues to evolve rapidly, building on a solid diagnostic foundation based on H&E and i... 3 years ago | 61 mins Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC Prof Dr EMD (Ed) Schuuring & Prof Dr HJM (Harry) Groen Join Dr. Ed Schuuring and Dr. Harry Groen, University Medical Center Groningen, The Netherlands, to explore the role of immunohistochemistry (IHC) in ... 5 years ago | 56 mins Module 2: Ventana PD-L1 (SP263) Assay NSCLC Evaluation Education Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell ... 3 years ago | 18 mins Module 3: Ventana PD-L1 (SP263) Assay NSCLC Guided Digital Case Review Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell ... 3 years ago | 71 mins Module 1: Ventana PD-L1 (SP263) NSCLC Assay Overview Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell ... 3 years ago | 11 mins Cerebral Organoids as a 3D Model for Glioma Amanda Linkous, Ph.D. The prognosis of patients with glioblastoma (GBM) remains dismal with a median survival of approximately 15 months. Current preclinical GBM models are... 4 years ago | 50 mins